Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals


  • Products Id :- GDHC507MD
  • |
  • Pages: 85
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2017 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2017 12

2.2.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 12

2.2.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 13

2.2.3 Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 13

2.2.4 Biogen to Enter into Licensing Agreement with Forward Pharma 14

2.2.5 Ipsen to Acquire Oncology Assets from Merrimack Pharma 15

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2017 17

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2017 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2017 19

3.1.1 Top M&A Deals in January 2017 20

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2016-January 2017 21

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2017 22

3.2.1 Top Equity Offering Deals in January 2017 23

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2016-January 2017 23

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2017 25

3.3.1 Top PE/VC Deals in January 2017 26

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2017 27

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2017 28

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-January 2017 29

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-January 2017 30

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2017 31

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2016-January 2017 32

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 33

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2017 34

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 35

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2016-January 2017 37

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2016-January 2017 38

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2016-January 2017 40

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2017 41

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2017 41

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2017 42

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2016-January 2017 43

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2016-January 2017 44

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2016-January 2017 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2016-January 2017 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2017 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2017 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2017 50

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 51

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2017 51

5.1.1 Oncology-Deals of the Month 52

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2017 54

5.2.1 Central Nervous System-Deals of the Month 55

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2017 57

5.3.1 Infectious Diseases-Deals of the Month 58

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2017 60

5.4.1 Cardiovascular-Deal of the Month 61

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2017 62

5.5.1 Immunology-Deals of the Month 63

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, January 2017 64

5.6.1 Gastrointestinal-Deal of the Month 65

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2017 67

5.7.1 Metabolic Disorders-Deal of the Month 68

6 Deal Summary by Geography 69

6.1 Pharmaceuticals & Healthcare, North America Deals, January 2017 69

6.1.1 North America-Deals of the Month 70

6.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2017 74

6.2.1 Europe-Deals of the Month 75

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2017 76

6.3.1 Asia-Pacific-Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2017 79

6.4.1 Rest of the World-Deals of the Month 80

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 81

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2016-January 2017 81

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2016-January 2017 82

8 Further Information 83

8.1 Methodology 83

8.2 About GlobalData 84

8.3 Contact Us 84

8.4 Disclosure information 84

8.5 Disclaimer 85

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2016-January 2017 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2017 17

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2017 18

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2016-January 2017 19

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016-January 2017 21

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2016-January 2017 22

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016-January 2017 23

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2016-January 2017 25

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016-January 2017 27

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2017 28

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2017 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2016-January 2017 29

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2016-January 2017 31

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016-January 2017 32

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 33

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 35

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016-January 2017 37

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016-January 2017 38

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2016-January 2017 40

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2016-January 2017 41

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 42

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016-January 2017 43

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 44

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2016-January 2017 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2016-January 2017 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2016-January 2017 51

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2016-January 2017 54

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2016-January 2017 57

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2016-January 2017 60

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2016-January 2017 62

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 64

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 67

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2016-January 2017 69

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2016-January 2017 74

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2016-January 2017 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2016-January 2017 79

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2016-January 2017 81

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2016-January 2017 82

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2017 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2017 18

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 20

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2017 20

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2016-January 2017 21

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 23

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2017 23

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 24

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 26

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2017 26

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2016-January 2017 27

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2017 29

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2016-January 2017 30

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-January 2017 30

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2016-January 2017 31

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016-January 2017 32

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 33

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2017 34

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 36

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016-January 2017 39

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2016-January 2017 40

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 41

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2016-January 2017 42

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2016-January 2017 43

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2017 44

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2016-January 2017 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2017 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2017 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2017 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2017 50

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 52

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 55

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 58

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 61

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 63

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 65

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 68

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 70

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 75

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2016-January 2017 80

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2016-January 2017 81

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2016-January 2017 82

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 1000 INR 64350
Site License
USD 2000 INR 128700
Corporate User License
USD 3000 INR 193050

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com